Revance Therapeutics (RVNC) Tops Q1 EPS by 12c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• FedEx (FDX) PT Lowered to $397 at Bernstein SocGen Group
• Paychex beats fourth quarter EPS estimates, stock slides